Latest news with #CDNA
Yahoo
01-05-2025
- Business
- Yahoo
CareDx Inc (CDNA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic Investments
Release Date: April 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. CareDx Inc (NASDAQ:CDNA) reported a strong first quarter with a revenue increase of 18% year over year, reaching $84.7 million. The company achieved its seventh consecutive quarter of sequential testing volume growth, with testing services revenue up 15% year over year. CareDx Inc (NASDAQ:CDNA) ended the quarter with a robust cash balance of $231 million and no debt, providing financial stability. The company launched two expanded indications for Allosure, enhancing its product offerings for pediatric heart transplant patients and simultaneous pancreas kidney transplant patients. CareDx Inc (NASDAQ:CDNA) made significant strides in market access, adding 3.5 million new covered lives for Allomap PAP and 15.5 million for Allosure testing. Operating expenses increased, driven by investments in sales and marketing, which may impact profitability if not managed carefully. The company faced a $1.1 million write-off for aged receivables, indicating potential challenges in collections. CareDx Inc (NASDAQ:CDNA) is involved in a securities class action litigation, with an anticipated out-of-pocket expense of approximately $5.4 million. There was a muted start to the year in transplant procedures, which could impact future revenue growth if not addressed. The company anticipates a $5 million annual investment for the Epic integration, which could strain resources if not offset by increased efficiencies. Warning! GuruFocus has detected 5 Warning Signs with CDNA. Q: Did you see signs of surveillance volume starting to come back in the quarter, and where are we at in that process? A: John Hanna, CEO: Absolutely, we are seeing signs of that volume coming back. We made progress on surveillance testing protocols in the 4th quarter and in the 1st quarter, and we see surveillance testing and kidney volumes really leading our growth across all organs. Q: How should we be thinking about the rate of spend throughout the rest of the year, given the higher R&D and SGA expenses this quarter? A: Abhishek Jane, CFO: Operating expenses were up 6% year over year, but with revenue growth of 18%, this provides about 600 to 700 basis points improvement in operating expenses as a percent of revenue. The increase is primarily driven by sales and marketing investments, while R&D expenses remain flat. Q: Is the benefit of surveillance volumes getting pulled forward, or is it still expected in the back half of the year? A: John Hanna, CEO: We are not suggesting a pull forward. We anticipated some impact from weather and fires at the beginning of the quarter, but we are making progress on surveillance testing. We expect growth in Q2 as centers reinitiate protocols and gradually increase volumes. Q: What are your thoughts on the potential issuance of new LCDs for transplant testing by the MACs? A: John Hanna, CEO: The data supporting surveillance testing has grown significantly. We saw a press release from the agency in August about potential new LCDs, but we don't have a timeline. We continue to push forward with studies like the KOR study to solidify the position for coverage. Q: Can you discuss the impact of the new CPT code for Allosure and how it leads to greater in-network coverage and higher ASP per test? A: John Hanna, CEO: The new Allosure-specific code allows us to contract with third-party payers and get in-network, which facilitates first-pass claim payments at contracted rates. This should help convert coverage policies into contracts, improving ASPs. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
San Francisco Chronicle
30-04-2025
- Business
- San Francisco Chronicle
CareDx: Q1 Earnings Snapshot
BRISBANE, Calif. (AP) — BRISBANE, Calif. (AP) — CareDx Inc. (CDNA) on Wednesday reported a loss of $10.4 million in its first quarter. On a per-share basis, the Brisbane, California-based company said it had a loss of 19 cents. Earnings, adjusted for stock option expense and non-recurring costs, were 9 cents per share. The molecular diagnostics company posted revenue of $84.7 million in the period, which did not meet Street forecasts. Three analysts surveyed by Zacks expected $84.9 million. CareDx shares have fallen 21% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $16.88, more than doubling in the last 12 months.
Yahoo
17-04-2025
- Business
- Yahoo
Should You Buy Advanced Micro Devices (AMD) Stock Before May 6?
Advanced Micro Devices (NASDAQ: AMD) supplies some of the world's best semiconductors, including a growing portfolio of chips specifically designed to handle artificial intelligence (AI) workloads in data centers and personal computers. AMD is scheduled to report its financial results for the first quarter of 2025 on May 6. Investors can expect to learn more about the company's progress, and perhaps even receive an updated forecast from CEO Lisa Su regarding AI chip sales for 2025. The stock is currently trading 54% below its record high from 2024. Some of that downside occurred after April 2, when President Donald Trump imposed sweeping tariffs on America's trading partners. The stock is now at a very attractive valuation, so is this a good opportunity for investors to buy ahead of the May 6 report? AMD launched its MI300X AI graphics processing unit (GPU) for the data center in late 2023. It quickly won over several top AI developers like Meta Platforms, Microsoft, and Oracle, some of which yielded better performance and lower costs compared to using Nvidia's H100 (which was leading the industry at the time). AMD has since launched the more powerful MI325X, and it's gearing up to start shipping a brand new lineup called the MI350 series, which is based on a fresh GPU architecture called CDNA (Compute DNA) 4. This architecture offers an eye-popping performance increase of 35 times compared to CDNA 3 chips like the MI300X. It will rival Nvidia's Blackwell architecture, which is currently the benchmark for the industry. The company started sending MI350 samples to customers during the first quarter of 2025, with production expected to ramp up into the middle of the year. It's likely to be AMD's most popular lineup of data center GPUs so far, because their increased processing power could pave the way for some of the most advanced AI models developed to date. In fact, Oracle recently announced plans to build a cluster of 30,000 of the upcoming MI355X GPUs, which might be a sign of things to come from other customers. Investors are likely to receive an update on the production and demand picture when AMD reports its first-quarter financial results on May 6. AMD generated $25.8 billion in total revenue during 2024, which was a 14% increase from the prior year. However, the company's data center revenue soared by 94% to reach a record high of $12.6 billion. GPU sales alone accounted for $5 billion of that total, and Su predicts that this figure will scale into the tens of billions of dollars over the next few years. Investors should keep an eye out for an update on that forecast on May 6, especially now that many customers have sampled the MI350 series GPUs over the last few months. AMD also generated $7 billion in revenue in its client segment, which was a 52% year-over-year jump. This business unit is home to the company's Ryzen AI chips for personal computers, which enable powerful chatbots and other AI applications to run locally on-device. This creates a much faster user experience, and it means you can use the power of AI without an internet connection in some cases. The chipmaker's other two segments, gaming and embedded, didn't fare so well during 2024, which is partly why its stock has lost so much ground. Gaming revenue declined by 58%, but a recovery might be underway. The company recently released the hotly anticipated Radeon 9070 GPU, which many customers were waiting to buy. Revenue from the embedded segment, on the other hand, sank by 33% due to weak demand in primary markets like communications and industrials. Simply put, if AMD can return the gaming and embedded segments to growth in 2025 (as is expected), while continuing to deliver powerful growth in its AI businesses, the company could be in for a record year in 2025. Like Nvidia and many other industry heavyweights, AMD relies on Taiwan Semiconductor Manufacturing to fabricate a significant portion of its chips. Earlier this month, President Trump imposed a 10% tariff on all goods imported into the U.S., in addition to another "reciprocal" tariff of 32% on Taiwan specifically (which was recently paused for 90 days). The president exempted semiconductors from these penalties, but they will still affect many of AMD's customers, which could force them to reduce their AI infrastructure budgets. As a result, it's possible that Su will not increase her 2025 sales forecast for GPUs when AMD reports its first-quarter results on May 6, which is a key risk to the stock. Nevertheless, President Trump has pulled this policy lever before. He imposed a series of tariffs on America's trading partners in 2018, which contributed to a near-20% decline in the S&P 500. But as we now know, the market -- and the broader economy -- recovered just fine in the years that followed. On that note, it might be a good idea to set May 6 aside and focus on AMD's long-term potential, especially given its current stock price. It trades at a price-to-earnings (P/E) ratio of 28.2, which is a 31% discount to Nvidia's P/E ratio of 37.1. Moreover, based on Wall Street's average earnings-per-share forecast of $4.65 for 2025 (provided by Yahoo! Finance), AMD stock trades at a forward P/E ratio of just 20.1. In other words, the stock would have to climb by 40% by the end of this year just to maintain its current P/E ratio. There could be some volatility surrounding AMD's upcoming financial report on May 6, depending on what Su tells investors about AI demand. However, investors could do well if they buy the stock at the current price regardless, as long as they can maintain a long-term horizon of three to five years. Before you buy stock in Advanced Micro Devices, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Advanced Micro Devices wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $502,231!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $678,552!* Now, it's worth noting Stock Advisor's total average return is 800% — a market-crushing outperformance compared to 156% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 14, 2025 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Meta Platforms, Microsoft, Oracle, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Should You Buy Advanced Micro Devices (AMD) Stock Before May 6? was originally published by The Motley Fool Sign in to access your portfolio
Associated Press
21-02-2025
- Business
- Associated Press
Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
SAN DIEGO--(BUSINESS WIRE)--Feb 21, 2025-- Johnson Fistel, LLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 30, 2020 and February 24, 2022, certain CareDX insiders allegedly caused the company to issue false and misleading public statements regarding its compliance with health care laws and its purported revenue growth. However, beginning on October 28, 2021, CareDx made its first in a series of public disclosures announcing that the company was facing multiple government investigations and that CareDx's financial results were far lower than it had previously claimed. By the time the company made its final disclosure on November 3, 2022, the price of CareDx's shares had plummeted by over 77.22%. Current stockholders who have held their CareDx stock since at least January 2021, and still hold today are encouraged to contact Johnson Fistel to discuss their legal rights in this matter. You can click or copy and paste the following link to join this investigation: About Johnson Fistel, LLP: Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, LLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content. View source version on 501 W. Broadway, Suite 800, San Diego, CA 92101 Copyright Business Wire 2025. PUB: 02/21/2025 09:43 AM/DISC: 02/21/2025 09:43 AM
